Granted Patent
B2
US 8,877,791 · App. 12/376,285 · Granted Nov 4, 2014
Inhibitors of pyruvate kinase and methods of treating disease
Inventors:
Lewis Cantley (Cambridge, MA); Matthew G. Vander Heiden (Somerville, MA); Heather R. Christofk (Carlsbad, CA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides pharmaceutical compositions, kits, and methods of treating cancer, diabetes, obesity, autoimmune disease, and benign prostatic hyperplasia using compounds that selectively inhibit pyruvate kinase M2 and an assay measuring chemical modulation of pyruvate kinase activity.
Claims (2)
1. A pharmaceutical composition comprising a compound selected from:
and a pharmaceutically acceptable excipient, wherein said pharmaceutical composition is formulated for oral administration in unit dosage form, for topical administration, or for intravenous administration.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Jun 27, 2018
From: BETH ISRAEL DEACONESS MEDICAL CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046443/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 3, 2010
From: CANTLEY, LEWIS; VANDER HEIDEN, MATTHEW G.; CHRISTOFK, HEATHER R.
To: BETH ISRAEL DEACONESS MEDICAL CENTER
Reel/Frame 023891/0922 →
Continuity (2)
Provisional Application
60835821
· Aug 4, 2006